BCM Advisors’s AbbVie ABBV Stock Holding History

BCM Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-189	Closed	-$12K	–	34
2016 Q4	$12K	Buy	+189	New	+$11.5K	0.01%	76

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

BCM Advisors's ABBV Position: Q1 2017 in Review

BCM Advisors sold out of AbbVie (ABBV) in Q1 2017, closing a stake of 189 shares — an estimated $12K sold.

BCM Advisors first reported a position in ABBV in Q4 2016 and held it in 1 quarter. The position peaked at $12K in Q4 2016. 1,727 funds tracked by Wall St. Rank hold ABBV as of Q1 2017.

BCM Advisors reported no remaining AbbVie position as of Q1 2017 after selling out during the quarter.
BCM Advisors sold 189 AbbVie shares in Q1 2017, an estimated $12K.
BCM Advisors first reported a position in AbbVie in Q4 2016 and held it in 1 quarter.
BCM Advisors's AbbVie position peaked at $12K in Q4 2016.
1,727 funds tracked by Wall St. Rank held AbbVie as of Q1 2017.

Based on BCM Advisors's 13F filing for Q1 2017, filed 12 May 2017.